Evaluation the effect of 17-alpha hydroxyprogesterone caproate on gestational diabetes mellitus in pregnant women at risk for preterm birth

Authors

Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The mellitus exact role of 17-alpha hydroxyprogesterone caproate in increasing the rate of gestational diabetes mellitus (GDM) is still unclear. This study was aimed to investigate the association of treatment with 17-alpha hydroxyprogesterone caproate with GDM in pregnant women who are at risk for preterm birth (PTB).
Materials and Methods: In this clinical trial, 200 singleton pregnant women included 100 pregnant women at risk for PTB or with history of PTB as case group (received weekly injections of 17-alpha hydroxyprogesterone caproate) and 100 healthy pregnant women without history of PTB as control group (did not receive any drug) were evaluated. All women followed until detect or reject of GDM, and abnormal glucose challenge test (GCT) and GDM were calculated in all of them.
Results: During study follow-up, 36 women in both groups were excluded and 81 cases 83 controls completed the study and analyzed. Mean of GCT in all studied pregnant women was 128.2 ± 18.1, whereas, in cases was higher than controls but no significant difference was noted between groups (P = 0.56). Abnormality in GCT was observed in 32 (19.5%) of 164 studied women, (18 of cases and 14 of controls), which was not statistically significant (P = 0.34). The frequency of GDM among all studied women was 7.9% (13 of 164), 7 of cases and 6 of controls, which was not significant (P = 0.74).
Conclusion: In summary, results demonstrated that weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of GDM in pregnant women at risk for PTB.

Keywords

1.
Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75-84.  Back to cited text no. 1
    
2.
Roberts CL, Morris JM, Rickard KR, Giles WB, Simpson JM, Kotsiou G, et al. Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]. BMC Pregnancy Childbirth 2011;11:19.  Back to cited text no. 2
    
3.
Hoyert DL, Mathews TJ, Menacker F, Strobino DM, Guyer B. Annual summary of vital statistics: 2004. Pediatrics 2006;117:168-83.  Back to cited text no. 3
    
4.
Mattison DR, Damus K, Fiore E, Petrini J, Alter C. Preterm delivery: A public health perspective. Paediatr Perinat Epidemiol 2001;15 Suppl 2:7-16.  Back to cited text no. 4
    
5.
Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, et al. The worldwide incidence of preterm birth: A systematic review of maternal mortality and morbidity. Bull World Health Organ 2010;88:31-8.  Back to cited text no. 5
    
6.
Green NS, Damus K, Simpson JL, Iams J, Reece EA, Hobel CJ, et al. Research agenda for preterm birth: Recommendations from the March of Dimes. Am J Obstet Gynecol 2005;193:626-35.  Back to cited text no. 6
    
7.
Creasy RK. Preterm birth prevention: Where are we? Am J Obstet Gynecol 1993;168:1223-30.  Back to cited text no. 7
    
8.
Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85.  Back to cited text no. 8
    
9.
Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24.  Back to cited text no. 9
    
10.
American College of Obstetricians and Gynecologists Committee Opinion. Use of progesterone to prevent preterm birth. Obstet Gynecol 2008;112:963-5.  Back to cited text no. 10
    
11.
Gyamfi C, Horton AL, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, et al. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am J Obstet Gynecol 2009;201:392.e1-5.  Back to cited text no. 11
    
12.
Picard F, Wanatabe M, Schoonjans K, Lydon J, O'Malley BW, Auwerx J. Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta -cell proliferation. Proc Natl Acad Sci U S A 2002;99:15644-8.  Back to cited text no. 12
    
13.
Kjos SL, Buchanan TA. Gestational diabetes mellitus. N Engl J Med 1999;341:1749-56.  Back to cited text no. 13
    
14.
Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: A systematic review. Lancet 2006;367:1066-74.  Back to cited text no. 14
    
15.
Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ, et al. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007;30:2277-80.  Back to cited text no. 15
    
16.
Meis PJ, Society for Maternal-Fetal Medicine. 17 hydroxyprogesterone for the prevention of preterm delivery. Obstet Gynecol 2005;105:1128-35.  Back to cited text no. 16
    
17.
Carr DB, Gabbe S. Gestational diabetes: Detection, management, and implications. Clin Diabetes 1998;16:1-17.  Back to cited text no. 17
    
18.
Wolfe K, Dearmond C, How H, Henderson ZT, Sibai B. The rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17a-hydroxyprogesterone caproate. Am J Perinatol 2011;28:741-6.  Back to cited text no. 18
    
19.
Waters TP, Schultz BA, Mercer BM, Catalano PM. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy. Obstet Gynecol 2009;114:45-9.  Back to cited text no. 19